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Introduction {#sec1}
============

Seasonal influenza vaccines offer protection against two influenza A virus subtypes, H1N1 and H3N2, as well as against influenza B virus. However, the effectiveness of seasonal influenza vaccines has been disappointing, especially for H3N2 viruses ([@bib2]). Their low effectiveness, other than occasional virus mismatch, can be attributed to the egg-based production process ([@bib35], [@bib37], [@bib46], [@bib47]). Influenza virus hemagglutinin (HA) engages the host sialylated glycan receptor at the receptor-binding site (RBS) to initiate the virus life cycle. Growth of the virus in eggs occurs in the chorioallantoic membrane, which contains sialylated glycans that are short and are predominantly α2-3 linked (avian-type receptors) ([@bib38]). In contrast, sialylated glycans in human ciliated tracheal epithelial cells, which are the natural host cells for human influenza virus, are predominantly α2-6 linked (human-type receptors) ([@bib8]). Furthermore, the receptor specificity of recent human H3N2 viruses has evolved to be mainly for long, branched α2-6 sialylated glycans ([@bib33]). There is also a strong selection pressure for human H3N2 viruses to acquire mutations in the HA RBS during passaging in eggs to adapt back to the avian-type receptors present in the chorioallantoic membrane. Since the HA RBS partially overlaps with several major antigenic sites ([@bib41], [@bib42], [@bib44]), egg-adaptive mutations can dramatically alter HA antigenicity and reduce the effectiveness of seasonal influenza vaccines ([@bib35], [@bib37], [@bib46], [@bib47]). While such problems can be resolved by cell-based or recombinant influenza vaccines, most influenza vaccines available on the market remain egg based because of low production cost and existing infrastructure for their annual production ([@bib16]).

Several egg-adaptive mutations on the HA of human H3N2 viruses, such as H156Q ([@bib19], [@bib37]), L194P ([@bib7], [@bib34], [@bib46]), and T160K (loss of glycosylation) ([@bib47]), have been shown to affect antigenicity. However, other egg-adaptive HA mutations on human H3N2 viruses, such as H183L ([@bib25]), G186V ([@bib1], [@bib24], [@bib25], [@bib32], [@bib40]), A196T ([@bib24]), S219F ([@bib40]), V226A ([@bib25]), and V226I ([@bib25], [@bib40]), minimally impact antigenicity. While egg-adaptive mutations are critical for high-yield production of egg-based seasonal influenza vaccines, the ideal egg-based vaccine should only carry those egg-adaptive mutations that minimally affect antigenicity. As egg-based vaccines are likely to remain the major global preventive measures against seasonal influenza viruses in the foreseeable future, it is important to characterize the evolution of the influenza virus during egg adaptation.

Based on sequence database analysis and virus rescue experiments, this study revealed that the two most common egg-adaptive mutations on H3N2 HA, namely G186V and L194P, are incompatible. In other words, the HA G186V/L194P double mutant was not viable despite each of the single mutants being viable. Passaging the G186V mutant in eggs could prevent the emergence of the L194P mutation and vice versa. Structural analysis illustrated that mutations G186V and L194P had opposing structural effects. The relative height of the HA RBS is increased by G186V but decreased by L194P. This structural variation between G186V and L194P then leads to differences in the receptor-binding modes. When mutations G186V and L194P are both present, the HA RBS is disrupted, explaining the incompatibility of G186V and L194P. Consistent with previous studies ([@bib1], [@bib7], [@bib24], [@bib25], [@bib32], [@bib34], [@bib40], [@bib46]), we also showed that G186V has minimal antigenic effect, whereas L194P strongly impacts antigenicity. In summary, this study reveals and characterizes two mutually exclusive evolutionary trajectories for egg adaptation of human H3N2 viruses, which provides important insights into the seed-strain selection for egg-based seasonal influenza vaccines.

Results {#sec2}
=======

Major Egg-Adaptive Mutations from Sequence Database {#sec2.1}
---------------------------------------------------

Egg-adaptive mutations can be readily observed after passaging human H3N2 clinical isolates in embryonated chicken eggs. To identify such mutations and ascertain their prevalence, HA protein sequences of influenza clinical isolates along with their passaging history were obtained from Global Initiative for Sharing Avian Influenza Data (GISAID; <http://gisaid.org>). H3 numbering is used in this study. Nine mutations, namely H156Q, H156R, H183L, G186V, L194P, S219Y, S219F, N246H, and N246S, were classified as the major egg-adaptive mutations (see [STAR Methods](#sec4){ref-type="sec"}; [Figures 1](#fig1){ref-type="fig"}A and 1B; [Table S1](#mmc1){ref-type="supplementary-material"}). These observations are consistent with previous studies, which showed that growth of the H3N2 virus in eggs can be enhanced by H183L ([@bib25]), G186V ([@bib1], [@bib25], [@bib39], [@bib40]), L194P ([@bib7], [@bib17], [@bib39]), S219Y ([@bib28], [@bib32], [@bib39]), S219F ([@bib32], [@bib40]), and loss of a glycosylation site at position 246 ([@bib1]). These seven major egg-adaptive mutations are all located within or adjacent to the HA RBS ([Figure 1](#fig1){ref-type="fig"}B). Among them, G186V and L194P, which are located on opposite sides of the 190-helix, had particularly high-occurrence frequencies ([Figure 1](#fig1){ref-type="fig"}A).Figure 1Egg-Adaptive Mutations in Human H3N2 Virus(A) Occurrence frequencies of seven major egg-adaptive mutations in egg-passaged human isolates from different years are shown. Mutations are numbered according to H3 numbering. The absolute residue numberings (from the first Met in the HA protein as 1) for residues 156, 183, 186, 194, 219, and 246, are 172, 199, 202, 210, 235, and 262, respectively.(B) The Cα positions of the major egg-adaptive mutations are shown on the HA structure as teal spheres. The binding site for the sialic acid is shaded by a yellow oval.(C) For each of the nine representative vaccine strains listed in [Table S2](#mmc1){ref-type="supplementary-material"}, the amino-acid identities at residues 156, 183, 186, 194, 219, and 246 (H3 numbering) are shown. Egg-adaptive mutations are highlighted in yellow. Of note, the egg-adaptive mutation G186E in A/South Australia/55/2014 (IVR-175) was seldom observed during egg adaptation. Two egg-adapted strains that were derived from A/Brisbane/10/2007, namely NYMC X-171 (GISAID: EPI_ISL_23300) and IVR-147 (GISAID: EPI_ISL_20693), are also included here for comparison.(D) A/Kansas/14/2017 is the H3N2 vaccine strain for the 2019--2020 northern hemisphere influenza season. The amino-acid identities at residues 156, 183, 186, 194, 219, and 246 are shown for four egg-adapted strains that were derived from A/Kansas/14/2017. The sequences were downloaded from GISAID with the following accession numbers: IVR-195 (GISAID: EPI_ISL_346482), X-327 (GISAID: EPI_ISL_346457), CBER-22C (GISAID: EPI_ISL_346456), and CBER-22B/CDC19A (GISAID: EPI_ISL_346455). Egg-adaptive mutations are highlighted in yellow.

We further examined the protein sequences of nine H3N2 vaccine seed strains that were used for egg-based influenza vaccine production ([Table S2](#mmc1){ref-type="supplementary-material"}). Six of the nine major egg-adaptive mutations, H156Q, H156R, G186V, L194P, S219Y, and S219F, could be found in the vaccine seed strains ([Figure 1](#fig1){ref-type="fig"}C). The most commonly observed egg-adaptive mutations among these nine vaccine seed strains were G186V and L194P, each of which was carried by four vaccine seed strains. However, none of the nine vaccine seed strains carried both G186V and L194P.

The H3N2 vaccine seed stock for the 2009--2010 northern hemisphere influenza season was derived from A/Uruguay/716/2007, which was antigenically equivalent to A/Brisbane/10/2007 (Bris07). A/Uruguay/716/2007 (NYMC X-175C) carried an egg-adaptive mutation, L194P, which has been extensively characterized, both structurally and antigenically, in our previous study using Bris07 HA ([@bib46]). Interestingly, two egg-adapted strains that were derived from Bris07, namely NYMC X-171 and IVR-147, carried different egg-adaptive mutations ([Figure 1](#fig1){ref-type="fig"}C). While NYMC X-171 carried mutation G186V but not L194P, IVR-147 carried mutation L194P but not G186V. Recently, the World Health Organization (WHO) announced A/Kansas/14/2017 (Kansas17) as the H3N2 vaccine strain for the 2019--2020 northern hemisphere influenza season. Therefore, we also examined the sequences of four egg-adapted strains that were derived from Kansas17 ([Figure 1](#fig1){ref-type="fig"}D). Consistent with our observations above, these four strains carried G186V but not L194P. Overall, this analysis demonstrates the potential clinical relevance of the egg-adaptive mutations and further suggests that G186V and L194P represent two distinct evolutionary pathways for egg adaptation.

Incompatibility of G186V and L194P {#sec2.2}
----------------------------------

Next, we aimed to investigate whether there was any relationship between G186V and L194P. Based on the egg-passaged human H3N2 virus in the GISAID database, a network diagram was constructed to visualize the co-occurrence of the nine major egg-adaptive mutations ([Figures 2](#fig2){ref-type="fig"}A; see [STAR Methods](#sec4){ref-type="sec"}). In this network diagram, each node represents an egg-adaptive mutation. Co-occurring mutations are connected by an edge. While G186V and L194P are the most commonly observed egg-adaptive mutations in H3N2, they did not co-occur in the same virus. We also performed a virus rescue experiment ([Figure 2](#fig2){ref-type="fig"}B). Both G186V and L194P single mutants could be rescued to a reasonable titer despite the lower titer of the L194P mutant. In contrast, the G186V/L194P double mutant could not be rescued. This result is consistent between two H3N2 genetic backgrounds: namely A/Victoria/361/2011 (Vic11) and Bris07. In fact, a previous study also failed to rescue the G186V/L194P double mutant in Bris07, as well as in another human H3N2 strain A/Wisconsin/67/05 ([@bib7]). Overall, our analyses show that G186V and L194P are incompatible.Figure 2Incompatibility of Egg-Adaptive Mutations HA L194P and G186V(A) A network diagram was constructed that describes the co-occurrence of egg-adaptive mutations and was based on the sequence analysis of egg-passaged human H3N2 viruses in the GISAID database. Each node represents an egg-adaptive mutation. Two mutations that co-occur more than once are connected by an edge. The width of the edge is proportional to the co-occurrence frequency. The occurrence frequency of each egg-adaptive mutation is color coded. L183 is not shown because it does not co-occur with other major egg-adaptive mutations in more than one isolate.(B) The fitness effects of different mutants were examined by a virus rescue experiment. The titer was measured by median tissue culture infectious dose (TCID~50~). Error bars indicate the standard deviation of three independent experiments.(C and D) Bris07 HA G186V mutant virus (C) and Bris07 HA L194P mutant virus (D) were passaged for five rounds in eggs. The emergence of egg-adaptive mutations in the receptor-binding domain (HA1 residues 117--265) was monitored by next-generation sequencing. Only those mutations that reached a minimum of 10% occurrence frequency are plotted. Three independent passaging experiments were performed for the Bris07 HA G186V mutant virus in (C) and one passaging experiment was performed for the Bris07 HA L194P mutant virus in (D). Passage 0 indicates the input virus.

We postulated that since G186V and L194P are mutually exclusive, the evolutionary trajectories of the H3N2 virus in eggs would be influenced by whichever mutation (i.e., G186V or L194P) appears first. We then performed an experiment by passaging the Bris07 G186V mutant to monitor the emergence of any mutations in the HA receptor-binding subdomain (HA1 residue 117--265) using next-generation sequencing. The G186V mutant was passaged in eggs in triplicate ([Figure 2](#fig2){ref-type="fig"}C). As expected, when the G186V mutant was passaged in eggs, the L194P mutation did not emerge. Instead, mutations I140K, I140R, N144K, H156R, H156Q, N189K, and D190N were observed with a frequency of \>10% in any passage, on the background of G186V. In comparison, when the L194P mutant was passaged in eggs, no mutation was able to reach a frequency of \>10% ([Figure 2](#fig2){ref-type="fig"}D). Overall, these results demonstrate that the evolutionary trajectories during H3N2 egg adaptation of G186V and L194P mutants are different, corroborating the incompatibility of G186V and L194P.

G186V Increases the Height of the HA RBS {#sec2.3}
----------------------------------------

Previously, we performed a thorough structural study of the L194P mutation ([@bib46]). To dissect the impact of the G186V mutation, a crystal structure of IVR-165 HA, which is the triple mutant H156Q/G186V/S219Y of Vic11 HA, was determined at a resolution of 2.25 Å ([Table S3](#mmc1){ref-type="supplementary-material"}). IVR-165 was the vaccine seed strain for the 2012--2013 influenza season ([Table S2](#mmc1){ref-type="supplementary-material"}). The HA structure of IVR-165 was compared with that of Vic11 by aligning their receptor-binding subdomains ([Figures 3](#fig3){ref-type="fig"}A and 3B). The distance between the 190-helix and 220-loop in IVR-165 HA RBS is slightly larger than that in the Vic11 HA RBS. Such a difference can be attributed to the G186V mutation, which causes the 190-helix to move away from the 220-loop through an increase in the side-chain volume. The other two egg-adaptive mutations H156Q and S219Y have little, if any, influence on the distance between the 190-helix and 220-loop. H156Q abolishes a hydrogen bond between the 150-loop and 190-helix ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), whereas S219Y stabilizes the N165 glycan from the neighboring promoter of the trimer by forming a stacking interaction with the glycan ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Therefore, the observed distance increase between the 190-helix and 220-loop is mainly a result of the G186V mutation.Figure 3Structural Comparison of IVR-165 HA and Vic11 HA(A) The HA RBS conformations of IVR-165 HA and Vic11 HA were compared by aligning their receptor-binding subdomains (HA1 residues 117--265). The slight expansion of the RBS due to the backbone shifts of the 190-helix and 220-loop is indicated by the arrows. IVR-165 HA that was used for structural determination was expressed recombinantly in insect cells (see [STAR Methods](#sec4){ref-type="sec"}).(B) A zoomed-in view of the RBS backbone shift.(C) The distances between the phenolic oxygen of Tyr 98 (OH~98~) and the Cα of residue 190 (Cα~190~) in different H3 strains were measured: Wy03: PDB [6BKN](pdb:6BKN){#intref0150} ([@bib43]), Fin04: PDB [2YP2](pdb:2YP2){#intref0155} ([@bib23]), HK05: PDB [2YP7](pdb:2YP7){#intref0160} ([@bib23]), Bris07: PDB [6AOR](pdb:6AOR){#intref0165} ([@bib46]), Bris07 (L194P): PDB [6AOP](pdb:6AOP){#intref0170} ([@bib46]), Vic11: PDB [4O5N](pdb:4O5N){#intref0175} ([@bib22]), and Mich14: PDB [6BKP](pdb:6BKP){#intref0180} ([@bib43]).

We further compared the height of the HA RBS of IVR-165 with that of other H3 strains ([Figure 3](#fig3){ref-type="fig"}C), namely A/Wyoming/3/2003 (Wy03) ([@bib43]), A/Finland/486/2004 (Fin04) ([@bib23]), A/Hong Kong/4443/2005 (HK05) ([@bib23]), Bris07 ([@bib46]), Vic11 ([@bib22]), and A/Michigan/15/2014 (Mich14) ([@bib43]). Besides IVR-165 HA, Wy03 HA also carried the G186V mutation. The heights of the RBS of Wy03 and IVR-165, as measured by the distance between OH~98~ and Cα~190~, are 9.3 and 9.5 Å, respectively. In comparison, those equivalent distances of Fin04, HK05, Bris07, Vic11, and Mich14 are in the range of 8.5--8.8Å. Overall, our structural analysis indicates that G186V increases the height and, hence, the size of the HA RBS.

G186V and L194P Lead to Differences in Receptor-Binding Mode {#sec2.4}
------------------------------------------------------------

To understand how G186V influences receptor binding, crystal structures of IVR-165 HA in complex the with avian receptor analog NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc (3′SLNLN) and the human receptor analog NeuAcα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc (6′SLNLN) were determined at 2.1 and 2.4 Å, respectively ([Table S3](#mmc1){ref-type="supplementary-material"}; [Figure S2](#mmc1){ref-type="supplementary-material"}). When binding to IVR-165 HA, 3′SLNLN adopts an extended conformation ([Figure 4](#fig4){ref-type="fig"}A), whereas 6′SLNLN adopts the canonical folded-back conformation ([Figure 4](#fig4){ref-type="fig"}B). We also observed a shift of the 220-loop toward the RBS during receptor binding ([Figures 4](#fig4){ref-type="fig"}A and 4B), which is a typical feature of recent human H3 viruses ([@bib23]). Similar to our previous observation with Bris07 L194P HA ([@bib46]), IVR-165 HA had negligible binding to the glycan array ([Figure S3](#mmc1){ref-type="supplementary-material"}). Of note, the glycan array has more stringent requirements for the detection of receptor binding than the X-ray structure analysis here, which involves soaking the crystals in a 100-fold molar excess of the receptor analogs. Being able to observe electron density for the receptor analogs in our crystal structures but no signal in the glycan array experiments indicates very weak binding to the receptor. This result also substantiates the notion that efficient replication of human influenza virus in chicken eggs does not require strong binding between HA and sialylated receptors ([@bib46]).Figure 4Structural Analysis of IVR-165 HA in Complex with Glycan Receptor Analogs(A and B) HA crystal structures of IVR-165 in complex with 3′SLNLN (A) and IVR-165 in complex with 6′SLNLN (B). The apo form is aligned on the complexes (blue) and colored in whitish gray. Glycan receptor analogs (3′SLNLN and 6′SLNLN) are colored in yellow and shown in stick representation. Hydrogen bonds are represented by black dashed lines.(C) The HA RBS conformations of IVR-165 HA and Bris07-L194P HA in complex with 3′SLNLN are compared. Structural alignment here and in (D) was performed using the receptor-binding subdomain (HA1 residues 117--265).(D) The RBS conformations of IVR-165 HA and Bris07 HA-L194P in complex with 6′SLNLN are compared.(E) The distance between equivalent Cαs of IVR-165 and Cαs of Bris07-L194P for each residue in the receptor-binding subdomain (HA1 residues 117--265) is shown. This analysis was performed on the structural alignment of IVR-165 and Bris07-L194P in complex with 3′SLNLN (upper panel) and in complex with 6′SLNLN (bottom panel). The major differences are seen in the 190-helix (shaded region).

Interestingly, noticeable differences can be observed between the receptor-binding modes of IVR-165 HA and that of the Bris07 HA L194P mutant ([@bib46]) when their receptor-binding subdomains (HA1 residues 117--265) are aligned ([Figures 4](#fig4){ref-type="fig"}C and 4D). GlcNAc-3 of the 3′SLNLN in complex with the Bris07 HA L194P mutant shifts away from the RBS as compared to that of 3′SLNLN in complex with IVR-165 HA ([Figure 4](#fig4){ref-type="fig"}C). For 6′SLNLN, Gal-2 is rotated by 90° when binding to Bris07 HA L194P ([@bib46]), as compared to the folded-back conformation when binding to IVR-165 HA ([Figure 4](#fig4){ref-type="fig"}D). Such differences in receptor binding can be attributed to the difference in the positioning of the 190-helix, i.e., the height of the RBS. In contrast to mutation G186V, which increases the RBS height, mutation L194P appears to decrease its height ([Figure 3](#fig3){ref-type="fig"}C). The distance between OH~98~ and Cα~190~ of the Bris07 HA L194P mutant is 8.3 Å, whereas that of Bris07 wild-type (WT) HA is 8.7 Å. We further measured the difference in backbone conformations between the receptor-binding subdomains of Bris07 HA and IVR-165 HA in their receptor-bound states ([Figure 4](#fig4){ref-type="fig"}E). This analysis reveals that shifts in the polypeptide backbone between Bris07 HA and IVR-165 HA in the 190-helix can be as large as 3 Å. Consequently, the difference in receptor-binding mode between IVR-165 HA and the Bris07 HA L194P mutant can be explained by the opposing structural effects of the G186V and L194P mutations.

HA G186V/L194P Double Mutant Disrupts the RBS {#sec2.5}
---------------------------------------------

With the knowledge that HA mutations G186V and L194P exert an opposing structural effect on the RBS ([Figures 3](#fig3){ref-type="fig"}C, [4](#fig4){ref-type="fig"}C, and 4D) and that the HA G186V/L194P double mutant was highly deleterious to the virus ([Figure 2](#fig2){ref-type="fig"}B), we were interested in examining the structural effect of the HA G186VL194P double mutant. Of note, the HA G186V/L194P double mutant abolishes virus replication but not HA protein expression. We were therefore able to recombinantly express and purify the Bris07 HA G186V/L194P double mutant. Crystal structures of the Bris07 HA G186V/L194P double mutant were determined at 2.25 Å, 2.1 Å, and 2.4 Å for the apo form, in complex with 3′SLNLN, and in complex with 6′SLNLN, respectively. In all three structures, the electron density for the 190-helix was very weak to absent compared to that of the Bris07 HA L194P single mutant ([Figure 5](#fig5){ref-type="fig"}), whose structure was previously determined in the same crystallization condition ([@bib46]). This observation indicates that the 190-helix in Bris07 HA G186V/L194P double mutant is extremely disordered. Consistently, the electron density for the receptor analogs 3′SLNLN and 6′SLNLN was also very weak in the complex with the Bris07 HA G186V/L194P double mutant. This structural analysis shows that combining HA mutations G186V and L194P dramatically destabilizes the 190-helix, causing a disruption of the RBS and also of antigenic site B, which is the major antigenic site in recent H3N2 viruses ([@bib3], [@bib34]).Figure 5Electron Density of the 190-HelixFinal 2Fo-Fc electron density maps for the HA receptor-binding site of the L194P mutant (top) and G186V/L194P double mutant (bottom) are represented in a blue mesh and contoured at 0.8 σ. Apo form (left panel), complex with 3′SLNLN (middle panel), and complex with 6′SLNLN (right panel). Final 2Fo-Fc electron density maps and coordinates for L194P mutant were retrieved from PDB [6AOP](pdb:6AOP){#intref0185} (apo form), PDB [6AOS](pdb:6AOS){#intref0190} (in complex with 3′SLNLN), and PDB [6AOT](pdb:6AOT){#intref0195} (in complex with 6′SLNLN) ([@bib46]). The HA of the Bris07 G186V/L194P double mutant was expressed recombinantly in insect cells (see [STAR Methods](#sec4){ref-type="sec"}).

G186V Imposes Minimum Change in Antigenicity {#sec2.6}
--------------------------------------------

Previously, we and others demonstrated that the HA antigenicity is significantly altered by the L194P mutation ([@bib7], [@bib34], [@bib46]), when using ferret sera ([@bib7]), human sera ([@bib46]), and human monoclonal antibodies ([@bib34], [@bib46]). Furthermore, based on a ferret study, L194P has been shown to significantly decrease virus immunogenicity ([@bib7]). In contrast, the G186V mutation has been shown to confer minimal HA antigenic differences ([@bib1], [@bib24], [@bib25], [@bib32], [@bib40]), using ferret sera ([@bib1], [@bib24], [@bib25], [@bib32]), sheep sera ([@bib40]), and mouse monoclonal antibodies ([@bib40]). Sera from ferrets that were immunized with a virus that carried the G186V mutation cross-react well with the WT virus, with only a 2-fold decrease in hemagglutination inhibition (HAI) titer when compared to the sera from ferrets that were immunized with the WT virus ([@bib1]). Here, we further performed a side-by-side comparison of the HA antigenic changes resulting from the G186V and L194P mutations. Sera from six mice that were immunized with unpassaged Bris07 WT virus (6:2 reassortant on PR8 backbone) were obtained. The immunization scheme consisted of infection of BALB/c mice with a non-adjuvanted virus followed by a boost with an Addavax-adjuvanted virus. An ELISA experiment was then performed to assess binding of these sera to Bris07 WT, G186V, and L194P recombinant HA proteins ([Figures 6](#fig6){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). For all serum samples, the binding to G186V was almost as strong as to WT, whereas binding to L194P was consistently weaker than to WT or G186V. We also tested binding of the HA-RBS-targeted antibody C05 ([@bib11]) to Bris07 WT, G186V, and L194P recombinant HA proteins using biolayer interferometry (BLI) ([Figure 6](#fig6){ref-type="fig"}B). C05 exhibited high affinity to WT (K~d~ = 1.0 ± 0.1 nM) and to G186V (K~d~ = 1.4 ± 0.2 nM), but very weak binding to L194P (\>1,000 nM). As a positive control, the stem-binding antibody CR9114 ([@bib9]) bound equally well to all three recombinant proteins ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Overall, these results substantiate the conclusion that G186V, unlike L194P ([@bib7], [@bib34], [@bib46]), exhibits minimal antigenic change ([@bib1], [@bib24], [@bib25], [@bib32]).Figure 6Antigenic Characterization of G186V and L194P(A) A total of 6 mice were immunized with Bris07 WT virus (6:2 reassortant on a PR8 backbone). Sera from immunized mice were tested for binding to WT, G186V mutant, and L194P mutant of recombinant Bris07 HA using ELISA. Percentage of WT binding was computed as binding level of the mutant at 1:1000 dilution of the serum sample/binding level of WT at 1:1000 dilution of the serum sample. Each line represents one serum sample. Statistical significance was determined using the paired Student's t test.(B) Biolayer interferometry (BLI) was used to measure the binding kinetics of anti-RBS C05 IgG against recombinant HAs of Bris07 WT, G186V mutant, and L194P mutant. Gray lines represent the response curve and colored lines represent the 1:1 binding model.

Discussion {#sec3}
==========

Non-additivity of mutational fitness effects is known as epistasis. Our previous studies have shown that epistasis is prevalent in the HA RBS ([@bib45]) and is relevant to antigenic drift of circulating human H3N2 influenza viruses ([@bib43]). This study further demonstrates that epistasis also exists between egg-adaptive mutations in the HA RBS. Mutational incompatibility between G186V and L194P is an extreme form of epistasis and can be attributed to their opposing structural effects. It is perhaps surprising that human H3N2 virus can adapt to eggs via two mutually exclusive pathways. Egg adaptation of influenza virus involves a receptor tropism switch, as required also in reverse for successful avian-to-human transmission that underlies human influenza pandemics ([@bib36]). However, it remains to be explored whether multiple mutational strategies can be employed by a single influenza strain to switch receptor specificity during avian-to-human transmission.

While the low effectiveness of egg-based, seasonal influenza vaccines has been attributed to HA egg-adaptive mutations that alter the antigenicity ([@bib35], [@bib37], [@bib46], [@bib47]), some HA egg-adaptive mutations do not affect antigenicity ([@bib1], [@bib24], [@bib25], [@bib32], [@bib40]). Interestingly, our work here revealed that different HA egg-adaptive mutations may not be compatible with each other. Our results raise the possibility that during egg-based seasonal vaccine production, the emergence of an egg-adaptive mutation with undesirable antigenic properties can be prevented by the presence of another egg-adaptive mutation by taking advantage of epistatic interactions.

Our study provides valuable information for the selection of vaccine seed strains with mutations that not only support efficient replication in eggs but also minimally affect the antigenicity when passaging in eggs. While the ideal approach would be to engineer the desired mutations into the vaccine seed stock using reverse genetics, such an approach is not allowed in certain countries because of their regulation on genetically modified organisms (GMOs). Alternatively, multiple egg-adapted isolates from the same parental strain can be plaque isolated and sequenced. Isolates that carry the desired mutations can then be selected for the vaccine seed strain. Of note, different egg-adapted isolates from the same parental strain often carry different mutations ([@bib1], [@bib32]). For example, both NYMC X-171 and IVR-147 were derived from the same parental strain Bris07 yet carried different egg-adaptive mutations ([Figure 1](#fig1){ref-type="fig"}C). Screening egg-adapted isolates that carry desired mutations may therefore represent a cost-effective approach for selecting the vaccine seed strain. Further studies will need to evaluate the complete inventory of possible egg-adaptive mutations, their antigenicity, and their compatibility with each other. Other related questions that need to be addressed include how different egg-adaptive mutations impact immunogenicity in different age cohorts and how antigenic imprinting ([@bib18], [@bib21]) influences the immune response elicited by egg-grown influenza vaccines.

Egg-based seasonal influenza vaccines have been the primary preventive against the influenza virus for more than 70 years ([@bib14]) despite the caveat of antigenic changes due to egg-adaptive mutations ([@bib35], [@bib37], [@bib46], [@bib47]). While our work has an immediate impact on the egg-based vaccine seed-strain selection process, a more radical approach is needed in the long run to provide substantial improvements in influenza vaccines. For example, Harding et al. recently developed a dual-HA influenza virus to enable efficient vaccine production in eggs without the need for egg adaptation ([@bib15]). Alternatively, several non-egg-based influenza vaccines have been developed ([@bib16]). Commercialization of cell-based ([@bib4]) and recombinant influenza vaccines ([@bib5]) that have been developed during the past decade will hopefully completely replace egg-based seasonal vaccines, albeit even if subject to a slow transition. However, the ultimate solution to influenza may require the development of a universal influenza vaccine that can offer long-lasting protection against multiple strains and subtypes ([@bib13]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIERDMEM mediumThermo Fisher ScientificCat\#11995065DMEM/F12 mediumThermo Fisher ScientificCat\#11320033ExpiCHO Expression System KitThermo Fisher ScientificCat\#A29133HyClone insect cell culture mediumGE HealthcareCat\#SH30280.03MEM non-essential amino acidsThermo Fisher ScientificCat\#11140050Trypsin-EDTAThermo Fisher ScientificCat\#25200056Penicillin-StreptomycinThermo Fisher ScientificCat\#15140122Fetal Bovine Serum (FBS)Thermo Fisher ScientificCat\#16000044Phosphate-buffered saline (PBS)Thermo Fisher ScientificCat\#14040133Lipofactamine 2000Thermo Fisher ScientificCat\#11668019Ni-NTA SuperflowQiagenCat\#30450HA protein sequencesGISAID; <http://gisaid.org>N/ADH10Bac competent cellsThermo Fisher ScientificCat\#10361012BALB/c miceLaboratory Animal Unit at HKUN/A**Antibodies**C05([@bib11])N/ACR9114([@bib9])N/AAnti-HIS mouse antibodyThermo Fisher ScientificCat\#MA1-21315; RRID: [AB_557403](nif-antibody:AB_557403){#interref200}Alexa647-linked anti-mouse IgGThermo Fisher ScientificCat\#A-21235; RRID: [AB_141693](nif-antibody:AB_141693){#interref205}**Chemicals and Recombinant Proteins**DpnINew England BiolabsCat\#R0176LTrypsinNew England BiolabsCat\#P8101STPCK-TrypsinThermo Fisher ScientificCat\#20233RNaseOUTThermo Fisher ScientificCat\#10777019Sodium chloride (NaCl)Sigma-AldrichCat\#S9888Tris BaseSigma-AldrichCat\#11814273001Concentrated hydrochloric acid (HCl)Sigma-AldrichCat\#H1758Sodium azide (NaN~3~)Sigma-AldrichCat\#S2002Bovine Serum Albumin (BSA)Sigma-AldrichCat\#A9418Tween 20Fisher ScientificCat\#BP337-5003'SLNLNIn-house synthesisN/A6'SLNLNIn-house synthesisN/AChemicals for protein crystallizationHampton ResearchN/AAddavaxInvivoGenCat\#vac-adx-10**Critical Commercial Assays**In-Fusion HD Cloning KitTakaraCat\#639647KOD Hot Start DNA PolymeraseEMD MilliporeCat\#71086-3PCR Clean-Up and Gel Extraction KitClontech LaboratoriesCat\#740609.250QIAprep Spin Miniprep KitQiagenCat\#27106NucleoBond Xtra MaxiClontech LaboratoriesCat\#740414.100Superscript III reverse transcriptaseThermo Fisher ScientificCat\#18080044QIAamp Viral RNA Mini KitQiagenCat\#52904QuikChange XL Mutagenesis kitStratageneCat\#200516**Deposited Data**Raw sequencing readsThis studyBioProject PRJNA532726X-ray coordinates and structure factorsThis studyPDB: [6NS9](pdb:6NS9){#intref0020}, [6NSA](pdb:6NSA){#intref0025}, [6NSB](pdb:6NSB){#intref0030}, [6NSC](pdb:6NSC){#intref0035}, [6NSF](pdb:6NSF){#intref0040}, [6NSG](pdb:6NSG){#intref0045}**Cell Lines**HEK 293T cellsN/AN/AMDCK-SIAT1 cellsSigma-AldrichCat\#05071502-1VLHEK 293S GnTI^-/-^ cellsATCCATCC CRL-3022ExpiCHO cellsThermo Fisher ScientificCat\#A29127Sf9 cellsATCCATCC CRL-1711High Five cellsThermo Fisher ScientificCat\#B85502**Oligonucleotides**Bris07-G186V-F:\
5\'-GGG GTT CAC CAC CCG GTT ACG GAC AAT GAC CAA-3\'Integrated DNA TechnologiesN/ABris07-G186V-R:\
5\'-TTG GTC ATT GTC CGT AAC CGG GTG GTG AAC CCC-3\'Integrated DNA TechnologiesN/ABris07-L194P-F:\
5\'-AAT GAC CAA ATC TTC CCG TAT GCT CAA GCA TCA-3\'Integrated DNA TechnologiesN/ABris07-L194P-R:\
5\'-TGA TGC TTG AGC ATA CGG GAA GAT TTG GTC ATT-3\'Integrated DNA TechnologiesN/AVic11-G186V-F:\
5\'-GGG GTT CAC CAC CCG GTT ACG GAC AAG GAC CAA-3\'Integrated DNA TechnologiesN/AVic11-G186V-R:\
5\'-TTG GTC CTT GTC CGT AAC CGG GTG GTG AAC CCC-3\'Integrated DNA TechnologiesN/AVic11-L194P-F:\
5′-AAG GAC CAA ATC TTC CCG TAT GCT CAA TCA TCA-3′Integrated DNA TechnologiesN/AVic11-L194P-R:\
5′-TGA TGA TTG AGC ATA CGG GAA GAT TTG GTC CTT-3′Integrated DNA TechnologiesN/A**Recombinant DNA**pFUSE-CHIg-hG1InvivoGenCat\#pfuse-hchg1pFUSE2-CLIg-hKInvivoGenCat\#pfuse2-hclkWSN 8-plasmid reverse genetics[@bib30]N/APR8 8-plasmid reverse genetics[@bib30]N/ApHW2000-chimeric Bris07 HA[@bib43]N/ApHW2000-chimeric Vic11 HA[@bib43]N/ApFast-Bris07 (H3 HA)[@bib11]N/ApFast-Vic11 (H3 HA)[@bib11]N/ApFast-IVR-165 (H3 HA)This studyN/A**Software and Algorithms**R<https://www.r-project.org>RRID: SCR_001905Python<https://www.python.org>RRID: SCR_008394MAFFT version 7.157b[@bib20]RRID: SCR_011811HKL2000[@bib31]RRID: SCR_015547Phaser[@bib26]RRID: SCR_014219Coot[@bib12]RRID: SCR_014222Refmac5[@bib29]RRID: SCR_014225MolProbity[@bib6]RRID: SCR_014226Custom scriptsThis study<https://github.com/wchnicholas/incompatible_egg_muts>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ian A. Wilson (<wilson@scripps.edu>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell Cultures {#sec4.3.1}

HEK 293T cells (human embryonic kidney cells, female) were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS), 1x MEM non-essential amino acids, and 100 U mL^-1^ of Penicillin-Streptomycin. MDCK-SIAT1 cells (Madin-Darby canine hidney cells with stable expression of human 2,6-sialtransferase, female) were maintained in DMEM medium supplemented with 10% FBS, 1x MEM non-essential amino acids, and 100 U mL^-1^ of Penicillin-Streptomycin. Sf9 cells (*Spodoptera frugiperda* ovarian cells, female) and High Five cells (*Trichoplusia ni* ovarian cells, female) were maintained HyClone insect cell culture medium. ExpiCHO cells (Chinese hamster ovary cells, female) were maintained according to the manufacturer's instructions (Thermo Fisher Scientific). HEK 293S GnTI^-/-^ cells (human embryonic kidney cells, female) were maintained in DMEM/F12 medium supplemented with 10% FBS, and 100 U mL^-1^ of Penicillin-Streptomycin.

### Influenza Virus {#sec4.3.2}

Recombinant influenza virus was generated based on the A/WSN/33 eight-plasmid reverse genetic system ([@bib30]). In this study, chimeric 6:2 reassortants were employed with the hemagglutinin (HA) and neuraminidase (NA) ectodomains being replaced by those from H3N2 viruses ([@bib45]). The HA protein sequence of A/Brisbane/10/2007 (Bris07) wild type (WT) was identical to GenBank: [ABW23422.1](ncbi-p:ABW23422.1){#intref0070}, which did not contain any egg-adaptive mutations. The HA protein sequence of IVR-165 was identical to GISAID: EPI551807. Transfection was performed in HEK 293T/MDCK-SIAT1 cells (Sigma-Aldrich, catalog number: 05071502-1VL) co-culture (ratio of 6:1) at 60% confluence using lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. At 24 hours post-transfection, cells were washed twice with phosphate-buffered saline (PBS) and cell culture medium was replaced with OPTI-MEM medium supplemented with 0.8 μg mL^−1^ tosyl phenylalanyl chloromethyl ketone (TPCK)-trypsin. Virus was harvested at 72 h post-transfection. For measuring virus titer by the TCID~50~ (median tissue culture infectious dose) assay, MDCK-SIAT1 cells were washed twice with PBS prior to the addition of virus, and OPTI-MEM medium was supplemented with 0.8 μg mL^−1^ TPCK-trypsin. The virus used for immunization and egg passaging was generated in the same manner, except that the A/PR/8/34 (PR8) eight-plasmid reverse genetic system was used instead to generate the 6:2 reassortant ([@bib30]).

Method Details {#sec4.4}
--------------

### Sequence Analysis {#sec4.4.1}

A total of 45,218 full-length human H3N2 HA protein sequences were downloaded from the Global Initiative for Sharing Avian Influenza Data (GISAID; <http://gisaid.org>). Sequences with ambiguous amino acids were removed. Sequence alignment was performed by MAFFT version 7.157b ([@bib20]). Passaging history was determined by parsing regular expression in FASTA headers as described ([@bib27]). Egg-adaptive mutations for a given position were defined as amino-acid variants that were observed only in egg-passaged isolates but not in isolates without any passage in a given year. Those egg-adaptive mutations that were observed in 5 out of 16 years (from 2003 to 2018) were classified as major egg-adaptive mutations.

### Construction of Individual Mutants {#sec4.4.2}

Individual mutants for validation experiments were constructed using the QuikChange XL Mutagenesis kit (Stratagene) according to the manufacturer's instructions.

### Serial Passages of the Influenza Viruses in Eggs {#sec4.4.3}

For each passaging experiment, three nine- to eleven-day embryonated chicken eggs (specific pathogen free) were inoculated with 0.2 ml of 10^5^ plaque-forming unit (PFU) ml^-1^ PR8-A/Brisbane/10/2007 (6:2 reassortant) HA mutant virus at 37°C for 48 hours. The allantoic fluid from each egg was collected and pooled. Five serial passages were performed for each passaging experiment. The viral RNA was extracted from the allantoic fluid using QIAamp Viral RNA Mini Kit (Qiagen Sciences). The extracted RNA was then reverse transcribed to cDNA using Superscript III reverse transcriptase (Life Technologies). The nucleotide region corresponding to the HA receptor-binding domain was amplified by polymerase chain reaction (PCR) using KOD DNA polymerase (EMD Millipore) according to the manufacturer's instructions, with primers: 5\'-CAC TCT TTC CCT ACA CGA CGC TCT TCC GAT CTX XXG GTC ACT AGT TGC CTC ATC CGG-3\' and 5\'-GAC TGG AGT TCA GAC GTG TGC TCT TCC GAT CTG GTG CAT CTG ATC TCA TTA TTG-3\'. The sequence XXX represents the barcode sequence for distinguishing samples from different passages. A second PCR was performed to add the rest of the adapter sequence and index to the amplicon using primers: 5'-AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT-3' and 5'-CAA GCA GAA GAC GGC ATA CGA GAT XXX XXX GTG ACT GGA GTT CAG ACG TGT GCT-3'. Positions annotated by an "X" represented the index sequence for distinguishing different passaging experiments. The final PCR products were submitted for next-generation sequencing using Illumina MiSeq PE300.

### Expression, Crystallization and Structural Determination {#sec4.4.4}

Briefly, the HA ectodomain, which corresponds to 11--329 (HA1) and 1--176 (HA2) based on H3 numbering, was fused with an N-terminal gp67 signal peptide and a C-terminal BirA biotinylation site, thrombin cleavage site, trimerization domain, and a His~6~ tag, and then cloned into a customized baculovirus transfer vector ([@bib10]). The HA protein sequence of A/Brisbane/10/2007 (Bris07) wild type (WT) was identical to GenBank: [ABW23422.1](ncbi-p:ABW23422.1){#intref0080}, which did not contain any egg-adaptive mutations. The HA protein sequence of IVR-165 was identical to GISAID: EPI551807. Bris07 mutants were derived from Bris07 WT using QuikChange XL Mutagenesis kit (Stratagene, see above). Recombinant bacmid DNA was generated using the Bac-to-Bac system (Life Technologies). Baculovirus was generated by transfecting purified bacmid DNA into Sf9 cells using FuGene HD (Promega) (Southampton, UK). HA was expressed by infecting suspension cultures of High Five cells (Life Technologies) with baculovirus at an MOI of 5 to 10 and incubating at 28°C with shaking at 110 rpm for 72 hours. The supernatant was concentrated. HA0 was purified by Ni-NTA and buffer exchanged into 20 mM Tris-HCl pH 8.0 and 150 mM NaCl. For crystallization, HA0 was treated with trypsin (New England Biolabs) to remove the C-terminal tag (BirA biotinylation site, thrombin cleavage site, trimerization domain, and the His~6~ tag) and to produce the cleaved mature HA (HA1/HA2). The trypsin-digested HA was then purified by size exclusion chromatography on a Hiload 16/90 Superdex 200 column (GE Healthcare) in 10 mM Tris pH 8.0, 50 mM NaCl, and 0.02% NaN~3~. HA crystal screening was carried out using our high-throughput, robotic CrystalMation system (Rigaku) using the sitting drop vapor diffusion method at 4°C and 20°C with each drop consisting of 100 nL protein + 100 nL precipitant. Diffraction-quality crystals for IVR-165 (10 mg/ml) were obtained using 44% 2-methyl-2,4-pentanediol, 0.1 M HEPES pH 7.0 as precipitant at 4°C. Diffraction-quality crystals for Bris07 G186V/L194P (10 mg/ml) were obtained from 0.1 M CAPS pH 10.5 and 29% PEG 400 at 20°C. To generate HA-receptor complexes, crystals were soaked in reservoir solution supplemented with 20 mM of receptor analogs for 2 hours. The resulting crystals were flash cooled, and stored in liquid nitrogen until data collection. Diffraction data were collected at the APS GM/CA-CAT 23ID-B and at the ALS 5.0.3, and then indexed, integrated and scaled using HKL2000 (HKL Research, Charlottesville, VA) ([@bib31]). The structure was solved by molecular replacement using Phaser ([@bib26]) with PDB [4O5N](pdb:4O5N){#intref0085} ([@bib22]) or PDB [6AOQ](pdb:6AOQ){#intref0090} ([@bib46]) as the molecular replacement model, modeled using Coot ([@bib12]), and refined using Refmac5 ([@bib29]). Ramachandran statistics were calculated using MolProbity ([@bib6]).

### Glycan Array Analysis {#sec4.4.5}

Recombinant trimeric HA0 was expressed in HEK 293S GnTI^-/-^ cells, purified and analyzed on a glycan array as previously described ([@bib33]). Briefly, soluble trimeric HA (50 μg mL^-1^) was pre-complexed with the anti-HIS mouse antibody (Thermo Fisher Scientific) and the Alexa647-linked anti-mouse IgG (Thermo Fisher Scientific) at 4:2:1 molar ratio for 15 minutes on ice in 50 μL PBST. This complex was incubated on the array surface in a humidified chamber for 60 minutes before washing and analysis using an Innoscan 1100AL microarray scanner (Innopsys, Chicago, IL). Fluorescent signal intensity was measured using Mapix (Innopsys) and mean intensity minus mean background of 4 replicate spots was calculated. A complete list of the glycans on the array is presented in [Data S1](#mmc2){ref-type="supplementary-material"}.

### Immunization of the Influenza Virus in Mice {#sec4.4.6}

Group of six 8-10 weeks old BALB/c mice were inoculated with 1,000 PFU of PR8-Bris07 (6:2 reassortant) wild type virus intranasally. At 16 days post-infection, the mice were further boosted by intraperitoneal injection of 1,000 PFU of same virus mixed with equal volume Addavax (InvivoGen, MF59-like Squalene Adjuvant). The sera of the immunized mice were collected at 24 days post-infection. The serum samples were kept in -20°C for further assay. All animal procedures were carried out under institutionally approved protocols (Approval number: 4884-18) at The University of Hong Kong.

### Antigen Binding Assay {#sec4.4.7}

A 96-well enzyme-linked immunosorbent assay (ELISA) plate (Nunc MaxiSorp) was first coated overnight with 100 ng per well of purified recombinant Bris07 HA protein in PBS buffer. The plates were then blocked with PBS containing 0.1% Tween 20 and 5% non-fat milk powder at room temperature for 2 hours. Each mouse serum sample was 2-fold serial diluted in PBS buffer and then added into the ELISA plates for 2-hour incubation at 37°C. After extensive washing with PBS containing 0.1% Tween 20, each well in the plate was further incubated with the HRP-sheep anti-mouse second antibody (1:5000, GE Healthcare) for 1 hour at 37°C. Followed by another extensive washing step, 100 μl mixture of solution A and B (R&D Systems) was added into each well. After 15 minutes incubation, the reaction was stopped by adding 50 μl of 2 M H~2~SO~4~ solution and analyzed by the Sunrise (Tecan, Grödig, Austria) absorbance microplate reader measured at 450 nm wavelength.

### IgG Expression and Purification {#sec4.4.8}

The C05 ([@bib11]) and CR9114 ([@bib9]) heavy chains and light chains were cloned into pFUSE-CHIg-hG1 and pFUSE2-CLIg-hK respectively. The plasmids were co-transfected into ExpiCHO cells (Thermo Fisher Scientific) at 2:1 ratio (light to heavy) using the Max titer protocol as described by the manufacturer's instructions for the ExpiCHO Expression System (Thermo Fisher Scientific). Full-length IgG proteins were purified from the supernatant using protein G column on AKTAexpress (GE Healthcare).

### Biolayer Interferometry Binding Assay {#sec4.4.9}

An Octet Red instrument (ForteBio) was employed for the biolayer interferometry binding assay. C05 IgG or CR9114 IgG at a concentration of 50 μg mL^-1^ was loaded onto the anti-human IgG Fc Capture (AHC) Biosensors. Binding kinetics were measured against the indicated HA at 250 nM, 500 nM, 1,000 nM, and 2,000 nM. The data were fit with a 1:1 binding model to estimate the K~d~.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

The p-value reported in [Figure 5](#fig5){ref-type="fig"}A was computed by the paired Student's t-test using the R software package.

Data and Software Availability {#sec4.6}
------------------------------

Raw sequencing data have been submitted to the NIH Short Read Archive under accession number: BioProject PRJNA532726. The X-ray coordinates and structure factors have been deposited in the RCSB Protein Data Bank under accession codes [6NS9](pdb:6NS9){#intref0095}, [6NSA](pdb:6NSA){#intref0100}, [6NSB](pdb:6NSB){#intref0105}, [6NSC](pdb:6NSC){#intref0110}, [6NSF](pdb:6NSF){#intref0115}, [6NSG](pdb:6NSG){#intref0120}. Custom python scripts for analyzing the co-occurrence frequencies of egg-adaptive mutations and the next-generation sequencing data have been deposited to <https://github.com/wchnicholas/incompatible_egg_muts>.

Web Resources {#app3}
=============

Global Initiative on Sharing All Influenza Data: <https://www.gisaid.org>

Supplemental Information {#app2}
========================

Document S1. Figures S1--S4 and Tables S1--S3Data S1. Glycan Array Compound List, Related to STAR MethodsDocument S2. Article plus Supplemental Information
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